Validity of a Vibrating Postural Device for the Treatment of Positional Obstructive Sleep Apnea (Postural)
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- OSA
- Sponsor
- Hospital Universitario Araba
- Enrollment
- 128
- Locations
- 1
- Primary Endpoint
- Apnea-Hypopnea Index (AHI)
- Status
- Completed
- Last Updated
- 6 years ago
Overview
Brief Summary
The objective of the study is validity of the effectiveness of a vibrating postural device in reduce the respiratory events (Apnea-Hypopnea Index-AHI) in patients with positional Obstructive Sleep Apnea (OSA).
Detailed Description
PURPOSE: The objective of the study is validity of the effectiveness of a vibrating postural device in reduce the respiratory events (Apnea-Hypopnea Index-AHI) in patients with positional Obstructive Sleep Apnea (OSA). The postural device is a vibratil device of 5x3 cm and a weight of about 30 grams integrating an accelerometer, a vibration and other sensors. The device is placed on the patient's forehead and when the device detects that the patient is in the supine position for 30 seconds or more, it starts a vibration, with increasing intensity, which ceases when the patient moves to lateral. METHODOLOGY: DESIGN: A multicenter, randomized parallel study controlled by placebo. It will include patients with diagnosis of positional OSA in the Sleep Units of the Hospital Universitario Araba and Hospital Arnau de Vilanova de Lleida. These patients will be randomized to three groups: Group A: General recommendation not sleeping in supine position; Group B: General recommendation not sleeping in supine position and the device without any activation (placebo); Group C: General recommendation not sleeping in supine position and the device activated (intervention group). Patients will undergo a basal conventional polysomnography (PSG) and after 12 weeks of treatment. In addition all patients will be visited at 1, 4, 8 and 12 weeks. PRIMARY OUTCOME: Validity of the effectiveness of a vibrating postural device in reduce the respiratory events in patients with positional Obstructive Sleep Apnea . SECONDARY OUTCOMES: To determine the effectiveness of the device for: 1) To reduce the time spent in supine position; 2)To maintain the quantity and the quality of sleep; 3) The side effects ; 4) Reduction of snoring; 5) Cost-effectiveness analysis.
Investigators
Joaquin Duran-Cantolla, MD
Principal Investigator. MD,PhD
Hospital Universitario Araba
Eligibility Criteria
Inclusion Criteria
- •Men and women ≥ 18 years old with diagnosis of positional OSA by PSG.
- •Apnea-Hypopnea index (AHI) ≥ 5
- •Apnea-Hypopnea index (AHI) in supine position doubling AHI in not supine position
- •Time in supine position ≥ 20% total sleep time.
- •Total sleep time at least 180 minutes
- •Not received any treatment for OSA in the last four weeks before inclusion at the study (Except hygienic measures)
- •Written informed consent signed.
Exclusion Criteria
- •Important problems of physical mobility
- •Body mass index \> 40kg/m²
- •Presence of any previously diagnosed sleep disorders (narcolepsy, insomnia...) or difficulty in adopting a standard sleeping position
- •Cognitive impairment, professional driver, use dangerous machinery, workers in three shifts, pregnant women or patients with severe disease.
- •Patients with severe cardiovascular and/or respiratory comorbidity
- •Excessive daytime sleepiness, Epworth scale \>12
- •Treatment with psychotropic drugs, central stimulant drugs, antidepressants, consumers of illegal drugs or consume \> 80 grams of ethanol per day.
Outcomes
Primary Outcomes
Apnea-Hypopnea Index (AHI)
Time Frame: three month
The effectiveness of the treatment will be measured by polysomnography (PSG), comparing the results of the basal PSG with the results of the final PSG (3 month), based on the results of the apnea hypopnea index (AHI).
Secondary Outcomes
- Side effects(three month)
- Reduction of snoring(three month)
- Maintain the quantity and the quality of sleep(three month)
- Epworth Sleepiness Scale(at baseline and at three month of follow-up)
- Blood pressure(three month)
- Quality of life (EuroQOL test)(at baseline and at three month of follow-up)
- Reduce the time spent in supine position(three month)
- Anthropometric variables (Body mass index)(three month)